|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 28, 2008. Alpha
4 Integrin and Tysabri
Our therapeutic strategy for treating autoimmune diseases is to
identify mechanisms common to autoimmune diseases and develop
novel therapeutics that stop the underlying causes of disease.
Alpha 4 integrin is a protein expressed by immune cells that
allows those cells to leave the bloodstream and invade target
tissues. Blocking alpha 4 integrin stops immune cells from
entering tissues.
Tysabri is an alpha 4 integrin antagonist. Tysabri
is designed to inhibit immune cells from leaving the
bloodstream and to prevent these immune cells from migrating
into chronically inflamed tissue where they may cause or
maintain inflammation. Tysabri was developed and is now
being commercialized by Elan in collaboration with Biogen Idec.
|
| |||||||